Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
about
Microbial Biotransformation to Obtain New AntifungalsAntifungal lock therapyAn automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicans virulence-related proteinsAntifungal application of nonantifungal drugsClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Multicenter study evaluating the Vitek MS system for identification of medically important yeasts.Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics.Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potencyInvasive candidiasis: update on current pharmacotherapy options and future perspectives.Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients.Current status of antifungal resistance and its impact on clinical practice.Antifungal drug resistance among Candida species: mechanisms and clinical impact.Molecular identification and antifungal susceptibility profiles of Candida parapsilosis complex species isolated from culture collection of clinical samples.Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations.In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of Candida Species.Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling.T2 Magnetic Resonance for Fungal Diagnosis.Anti-Candida Activity of New Azole Derivatives Alone and in Combination with Fluconazole.T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.Experimental therapy with azoles against Candida guilliermondii.An Update on Candida tropicalis Based on Basic and Clinical ApproachesAntifungal activity of geldanamycin alone or in combination with fluconazole against Candida species.Candida glabrata Biofilms: How Far Have We Come?Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B.Epidemiology of echinocandin resistance inPortrait of Matrix Gene Expression in Candida glabrata Biofilms with Stress Induced by Different Drugs.Review on fungal enzyme inhibitors – potential drug targets to manage human fungal infections
P2860
Q26770689-06F7BA55-39B1-4237-9958-530D40C197AAQ27025682-07AFB619-034F-4FC5-8491-3A705C38E0D9Q28544418-7D4ECDAF-144E-4738-B6B7-0B6E83B2406FQ30433553-843D8F69-470E-4DDF-8D6D-5B8EF704DF53Q34505582-5749A64E-F5B8-4B39-AB8E-4C205E9BF1F4Q34546811-CC2EA292-4391-4615-9A4D-E0B2C1F3AB17Q34711725-4D37EA68-76B7-4BA1-AADB-793B9D52BBBCQ35136379-2183DABB-75E9-4DBE-93BF-684565A0291BQ35170424-DE218FB1-F923-4270-B0B4-B832C4608BA4Q35635472-7B1BDBA2-2A0E-4F58-AE00-9461B4FB92E4Q35960887-3F9D0CF7-E0D4-492B-B915-E76B1CEDC666Q36158489-CFE0128E-5996-4A71-9202-FA13A84503FBQ37401889-1B69CF6B-8584-44A6-9040-670FA9425BFDQ38110850-82563F50-9C45-4B62-BE66-C2171243F2C4Q38149163-9766CD8E-A599-4633-A48C-43B78FF88000Q38205859-08F74A40-B914-4118-8C93-76B28138E421Q38511946-41D7DA56-083C-4782-95AC-B05833F80866Q38882704-0EF2B2DA-ED63-4B12-960E-46C891B76805Q39251474-3DC1121F-7E21-4F07-AAC4-3164668D759EQ40034825-34EB6F60-526C-4E32-B491-D3A3A1B1D603Q40323063-B7736F46-FA5F-4F07-BDAF-D92CCC60816BQ40454814-3E28AD80-4EC8-4261-B2AC-7690D15A46F1Q41228972-D8854A10-68EB-4F9F-B50F-B8BEE6138A98Q41546170-5A7E4980-C53E-41A0-97AF-8D87C2170121Q42657625-3FD17138-F711-4A5B-97C6-72B10E03E7CBQ42682766-E51AAE62-1415-40B9-B6CD-A559B1132081Q43821648-13168F61-2D04-4FBA-ABF5-FC77B138BC5FQ48163274-51BD9D30-8856-4544-B8DA-EFA445FC9343Q52761081-FFE405BD-CA8C-46A1-9FAE-3601DF617C60Q54156897-ED0F6167-A9B5-45F2-9F50-7791B9353277Q55516936-F359339F-B5D1-4648-8E74-2AB5437E1F60Q57705350-CDC2512D-690C-4A0C-A654-0BC09473A8FF
P2860
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Echinocandin resistance in Can ...... ty and therapeutic approaches.
@en
type
label
Echinocandin resistance in Can ...... ty and therapeutic approaches.
@en
prefLabel
Echinocandin resistance in Can ...... ty and therapeutic approaches.
@en
P2860
P356
P1476
Echinocandin resistance in Can ...... ity and therapeutic approaches
@en
P2093
Nicholas D Beyda
P2860
P304
P356
10.1345/APH.1R020
P407
P577
2012-07-17T00:00:00Z